Krystal Biotech (KRYS) Scheduled to Post Earnings on Monday

Krystal Biotech (NASDAQ:KRYS) is set to issue its quarterly earnings data before the market opens on Monday, May 6th. Analysts expect the company to announce earnings of $0.28 per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.82. The firm had revenue of $42.14 million for the quarter, compared to analyst estimates of $27.43 million. During the same period in the previous year, the firm posted ($1.25) EPS. On average, analysts expect Krystal Biotech to post $2 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Krystal Biotech Trading Up 0.5 %

Krystal Biotech stock opened at $161.10 on Friday. The company has a 50-day moving average price of $169.04 and a 200 day moving average price of $133.26. Krystal Biotech has a 12-month low of $82.09 and a 12-month high of $189.97. The stock has a market cap of $4.59 billion, a P/E ratio of 2,014.00 and a beta of 0.91.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the transaction, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total value of $829,400.00. Following the completion of the sale, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at $2,145,823.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the transaction, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,087 shares of company stock valued at $6,210,591. 14.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on KRYS. Citigroup raised their price target on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. William Blair restated an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Guggenheim upped their price target on Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Stifel Nicolaus reissued a “buy” rating and set a $204.00 price objective (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $200.00 target price on shares of Krystal Biotech in a research report on Monday, April 22nd. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Krystal Biotech has an average rating of “Buy” and an average target price of $171.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).